Pancreatic Cancer Research

ResearcherErasmus MCActive in the last 2 years

Joanne Verheij

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-1283-630X; OpenAlex author ID A5045590497. Sources: OpenAlex.

Their work

Papers
34 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
150
Papers, trials and grants by year

2016: 1 paper · 2017: none · 2018: 1 paper · 2019: none · 2020: 6 papers · 2021: 7 papers · 2022: 5 papers · 2023: 3 papers · 2024: 5 papers · 2025: 5 papers · 2026: 1 paper

Papers 34

  1. Transcriptome-Based Classification of Resected Pancreatic Ductal Adenocarcinoma Enhances Prognostic Modelling Accuracy of Overall Survival Following Adjuvant T… Co-author DOI 10.1002/ijc.70519↗
  2. Minimally Invasive vs Open Left Pancreatectomy for Resectable Pancreatic Cancer: Long-Term Results of the Randomized DIPLOMA Trial. Co-author DOI 10.1001/jamasurg.2025.4054↗
  3. Mucinous cystic neoplasms and simple mucinous cysts are two distinct precursors of pancreatic cancer: clinicopathological, genomic, and transcriptomic characte… Co-author DOI 10.1002/path.6437↗
  4. 10-year survival after resection of pancreatic ductal adenocarcinoma with pathological re-examination of a nationwide cohort. Co-author DOI 10.1016/j.ejca.2025.116099↗
  5. Tumor gene expression is associated with venous thromboembolism in patients with ductal pancreatic adenocarcinoma. Co-author DOI 10.1016/j.thromres.2024.109240↗
  6. 18F-Prostate-Specific Membrane Antigen PET/CT imaging for potentially resectable pancreatic cancer (PANSCAN-2): a phase I/II study. Co-author DOI 10.1186/s40644-025-00822-y↗
  7. Pathological Complete Response in Patients With Resected Pancreatic Adenocarcinoma After Preoperative Chemotherapy. Co-author DOI 10.1001/jamanetworkopen.2024.17625↗
  8. Implementation of Best Practices in Pancreatic Cancer Care in the Netherlands: A Stepped-Wedge Randomized Clinical Trial. Co-author DOI 10.1001/jamasurg.2023.7872↗
  9. Kinase activities in pancreatic ductal adenocarcinoma with prognostic and therapeutic avenues. Co-author DOI 10.1002/1878-0261.13625↗
  10. Transcriptome-based classification to predict FOLFIRINOX response in a real-world metastatic pancreatic cancer cohort. Co-author DOI 10.1016/j.trsl.2024.08.002↗
  11. Artificial Intelligence-based Segmentation of Residual Pancreatic Cancer in Resection Specimens Following Neoadjuvant Treatment (ISGPP-2): International Improv… Co-author DOI 10.1097/pas.0000000000002270↗
  12. Diagnostic performance of endoscopic tissue acquisition for pancreatic ductal adenocarcinoma in the PREOPANC and PREOPANC-2 trials. Co-author DOI 10.1016/j.hpb.2023.04.018↗
  13. Minimally invasive versus open distal pancreatectomy for resectable pancreatic cancer (DIPLOMA): an international randomised non-inferiority trial. Co-author DOI 10.1016/j.lanepe.2023.100673↗
  14. Nationwide Impact of Centralization, Neoadjuvant Therapy, Minimally Invasive Surgery, and Standardized Pathology Reporting on R0 Resection and Overall Survival… Co-author DOI 10.1245/s10434-023-13465-9↗
  15. Analysis of the glyco-code in pancreatic ductal adenocarcinoma identifies glycan-mediated immune regulatory circuits. Co-author DOI 10.1038/s42003-021-02934-0↗
  16. Impact of classical and basal-like molecular subtypes on overall survival in resected pancreatic cancer in the SPACIOUS-2 multicentre study. Co-author DOI 10.1093/bjs/znac272↗
  17. Histopathological tumour response scoring in resected pancreatic cancer following neoadjuvant therapy: international interobserver study (ISGPP-1). Co-author DOI 10.1093/bjs/znac350↗
  18. Nationwide Validation of the 8th American Joint Committee on Cancer TNM Staging System and Five Proposed Modifications for Resected Pancreatic Cancer. Co-author DOI 10.1245/s10434-022-11664-4↗
  19. Correction to: Nationwide Validation of the 8th American Joint Committee on Cancer TNM Staging System and Five Proposed Modifications for Resected Pancreatic C… Co-author DOI 10.1245/s10434-022-12182-z↗
  20. Microscopic resection margin status in pancreatic ductal adenocarcinoma - A nationwide analysis. Co-author DOI 10.1016/j.ejso.2020.11.145↗
  21. Amsterdam International Consensus Meeting: tumor response scoring in the pathology assessment of resected pancreatic cancer after neoadjuvant therapy. Last author DOI 10.1038/s41379-020-00683-9↗
  22. Readily available biomarkers predict poor survival in metastatic pancreatic cancer. Co-author DOI 10.1080/1354750x.2021.1893814↗
  23. Scoring of tumour response after neoadjuvant therapy in resected pancreatic cancer: systematic review. Co-author DOI 10.1093/bjs/znaa031↗
  24. Resection of the Portal-Superior Mesenteric Vein in Pancreatic Cancer: Pathological Assessment and Recurrence Patterns. Co-author DOI 10.1097/mpa.0000000000001897↗
  25. Minimally invasive versus open distal pancreatectomy for pancreatic ductal adenocarcinoma (DIPLOMA): study protocol for a randomized controlled trial. Co-author DOI 10.1186/s13063-021-05506-z↗
  26. Artificial Intelligence-Based Segmentation of Residual Tumor in Histopathology of Pancreatic Cancer after Neoadjuvant Treatment. Co-author DOI 10.3390/cancers13205089↗
  27. Circulating tumor DNA quantity is related to tumor volume and both predict survival in metastatic pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ijc.32586↗
  28. Nationwide trends in incidence, treatment and survival of pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.ejca.2019.11.002↗
  29. Unsupervised class discovery in pancreatic ductal adenocarcinoma reveals cell-intrinsic mesenchymal features and high concordance between existing classificati… Co-author DOI 10.1038/s41598-019-56826-9↗
  30. Molecular targets for diagnostic and intraoperative imaging of pancreatic ductal adenocarcinoma after neoadjuvant FOLFIRINOX treatment. Co-author DOI 10.1038/s41598-020-73242-6↗
  31. Impact of nationwide enhanced implementation of best practices in pancreatic cancer care (PACAP-1): a multicenter stepped-wedge cluster randomized controlled t… Co-author DOI 10.1186/s13063-020-4180-z↗
  32. High-grade mesenchymal pancreatic ductal adenocarcinoma drives stromal deactivation through CSF-1. Co-author DOI 10.15252/embr.201948780↗
  33. International Validation of the Eighth Edition of the American Joint Committee on Cancer (AJCC) TNM Staging System in Patients With Resected Pancreatic Cancer. Co-author DOI 10.1001/jamasurg.2018.3617↗
  34. Recent Advances in Pancreatic Cancer Surgery of Relevance to the Practicing Pathologist. Co-author DOI 10.1016/j.path.2016.05.002↗

Closest collaborators

The 25 strongest of 150 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Marc G. Besselink · 23 shared papers, 2016–2026 · strength 2.69
  2. Johanna W. Wilmink · 11 shared papers, 2020–2026 · strength 1.46
  3. Bert A. Bonsing · 11 shared papers, 2020–2025 · strength 1.40
  4. Maarten F. Bijlsma · 10 shared papers, 2020–2026 · strength 1.38
  5. Frederike Dijk · 9 shared papers, 2020–2026 · strength 1.27
  6. Lodewijk A.A. Brosens · 10 shared papers, 2021–2025 · strength 1.24
  7. Bas Groot Koerkamp · 10 shared papers, 2018–2025 · strength 1.15
  8. Geert Kazemier M · 8 shared papers, 2021–2026 · strength 1.14
  9. Hanneke W.M. van Laarhoven · 8 shared papers, 2020–2026 · strength 0.97
  10. Ignace H. J. T. de Hingh · 7 shared papers, 2020–2026 · strength 0.97
  11. Stijn R. van Roessel · 9 shared papers, 2018–2022 · strength 0.92
  12. Casper H.J. van Eijck · 7 shared papers, 2016–2026 · strength 0.84
  13. Vincent Erwin de Meijer · 6 shared papers, 2020–2026 · strength 0.82
  14. Izaak Quintus Molenaar · 7 shared papers, 2016–2025 · strength 0.75
  15. Boris V. Janssen · 6 shared papers, 2021–2024 · strength 0.73
  16. Hjalmar C. van Santvoort · 6 shared papers, 2020–2025 · strength 0.70
  17. Martijn W.J. Stommel · 5 shared papers, 2021–2026 · strength 0.69
  18. Michail Doukas · 4 shared papers, 2021–2025 · strength 0.61
  19. Lydia G. van der Geest · 4 shared papers, 2020–2025 · strength 0.55
  20. Elisa Giovannetti · 3 shared papers, 2022–2025 · strength 0.55
  21. Anthony James Gill · 4 shared papers, 2021–2025 · strength 0.50
  22. Eline C. Soer · 5 shared papers, 2020–2022 · strength 0.49
  23. Claudio Luchini · 4 shared papers, 2021–2025 · strength 0.49
  24. Caroline Sophie Verbeke · 4 shared papers, 2021–2024 · strength 0.48
  25. Marjolein Y.V. Homs · 3 shared papers, 2021–2025 · strength 0.46

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.